Monitoring of residual disease in chronic myelogenous leukemia: methodological approaches and clinical aspects.
Lion
T
T
CCRI, Vienna, Austria.
D014408:Biomarkers, Tumor / Q000032:analysis; D015139:Blotting, Southern; D004273:DNA, Neoplasm / Q000032:analysis; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D017404:In Situ Hybridization, Fluorescence; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D009363:Neoplasm Proteins / Q000032:analysis; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D007155:Immunologic Factors; D016898:Interferon-alpha; D009363:Neoplasm Proteins; D016044:Fusion Proteins, bcr-abl